Contineum Therapeutics, Inc. (CTNM)
| Market Cap | 530.51M +348.7% |
| Revenue (ttm) | n/a |
| Net Income | -58.44M |
| EPS | -1.91 |
| Shares Out | 37.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,888,531 |
| Open | 13.38 |
| Previous Close | 13.36 |
| Day's Range | 13.32 - 14.48 |
| 52-Week Range | 3.72 - 16.33 |
| Beta | 0.89 |
| Analysts | Strong Buy |
| Price Target | 22.33 (+57.36%) |
| Earnings Date | Aug 4, 2026 |
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitt... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CTNM stock is "Strong Buy." The 12-month stock price target is $22.33, which is an increase of 57.36% from the latest price.
News
Contineum Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Key focus is on advancing PIPE-791 in IPF, with phase II enrollment progressing and strong differentiation from competitors due to dosing convenience and safety. Additional programs in pain and MDD are advancing, supported by a robust financial position and strategic partnerships.
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
PIPE-791 demonstrated promising pain reduction and strong safety in early studies, with greater efficacy in osteoarthritis. The focus remains on IPF, where the drug may offer advantages in dosing, safety, and quality of life. The company is well-funded and progressing with robust clinical trials.
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum price target raised to $16 from $14 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Contineum (CTNM) to $16 from $14 and keeps an Equal Weight rating on the shares.
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Earnings release: Q1 2026
Contineum Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Contineum Therapeutics Quarterly report: Q1 2026
Contineum Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Contineum Therapeutics Slides: Corporate presentation
Contineum Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum reports positive topline data from exploratory PIPE-791 Phase 1b
Contineum (CTNM) Therapeutics reported positive topline data from its exploratory Phase 1b trial of PIPE-791, a potentially best-in-class selective antagonist of the lysophosphatidic acid 1 (LPA1) rec...
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Proxy statement: Proxy filing
Contineum Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Contineum Therapeutics Proxy statement: Proxy filing
Contineum Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Contineum Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is advancing two clinical-stage assets, PIPE-791 and PIPE-307, with a focus on pulmonary fibrosis and MDD. PIPE-791 differentiates through once-daily dosing, high receptor occupancy, and a strong safety profile, while PIPE-307 is partnered with J&J for rapid-onset MDD therapy. Key catalysts this year include PIPE-791 pain data, J&J’s MDD results, and BMS’s phase III readout.
Contineum price target raised to $20 from $14 at Baird
Baird analyst Charles Moore raised the firm’s price target on Contineum (CTNM) to $20 from $14 and keeps an Outperform rating on the shares. The firm updated its model following…
Contineum reports Q4 EPS (49c), consensus (39c)
Cash, cash equivalents and marketable securities were $262.9 million as of December 31, 2025. Contineum (CTNM) believes its cash resources are sufficient to fund its planned operations through mid-202...
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Annual report: Q4 2025
Contineum Therapeutics has published its Q4 2025 annual report on March 5, 2026.
Contineum Therapeutics Earnings release: Q4 2025
Contineum Therapeutics released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Contineum (CTNM) to Equal Weight from Overweight with a price target of $14, down from $23. The PIPE-307 Phase 2 VISTA study in RRMS did not yield…
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...